Corcept Therapeutics Inc $ 12.9 -0.24 (-1.83%)
Volume:
506,048
Avg Vol (1m):
1,078,021
Market Cap $:
1.47 Bil
Enterprise Value $:
1.24 Bil
P/E (TTM):
17.92
P/B:
4.40
Financial Strength | 10/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 300.84 | ||
| Equity-to-Asset | 0.91 | ||
| Debt-to-EBITDA | 0.01 | ||
| Interest Coverage | No Debt | ||
| Piotroski F-Score | 7 | ||
| Altman Z-Score | 29.39 | ||
| Beneish M-Score | -2.53 | ||
| WACC vs ROIC | |||
Profitability Rank | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 35.56 | ||
| Net Margin % | 30.41 | ||
| ROE % | 29.86 | ||
| ROA % | 26.67 | ||
| ROC (Joel Greenblatt) % | 3687.63 | ||
| 3-Year Revenue Growth Rate | 61.6 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 17.92 | ||
| Forward PE Ratio | 13.72 | ||
| PE Ratio without NRI | 17.92 | ||
| Price-to-Owner-Earnings | 18.94 | ||
| PB Ratio | 4.4 | ||
| PS Ratio | 5.56 | ||
| Price-to-Free-Cash-Flow | 14.68 | ||
| Price-to-Operating-Cash-Flow | 14.51 | ||
| EV-to-EBIT | 12.25 | ||
| EV-to-EBITDA | 12.05 | ||
| EV-to-Revenue | 4.36 | ||
| Current Ratio | 8.25 | ||
| Quick Ratio | 8.08 | ||
| Days Inventory | 332.2 | ||
| Days Sales Outstanding | 28.65 | ||
| Days Payable | 383.74 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.4 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 1.78 | ||
| Price-to-Median-PS-Value | 0.31 | ||
| Price-to-Graham-Number | 1.87 | ||
| Earnings Yield (Greenblatt) % | 8.16 |